Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health (ELAN) delivers innovative health solutions for pets and livestock worldwide. This dedicated news hub provides investors and industry professionals with essential updates on corporate developments, product innovations, and strategic initiatives shaping the animal health sector.
Access real-time press releases, earnings announcements, and regulatory filings alongside analysis of ELAN's advancements in veterinary pharmaceuticals. Our curated collection simplifies tracking of:
- Quarterly financial results and investor communications
- New product launches and FDA approvals
- Strategic partnerships and R&D milestones
- Industry leadership initiatives and sustainability efforts
Bookmark this page for streamlined access to verified ELAN updates. Combine our news feed with SEC filings and market analysis tools for comprehensive due diligence in the dynamic animal health market.
Elanco Animal Health (NYSE: ELAN) is expanding its shared value initiative in Sub-Saharan Africa, focused on improving livestock health and sustainability for small-scale farmers. The new project, MAHABA, aims to tackle tick infestations affecting up to 98% of cattle in Uganda and 80% in Nigeria. This initiative follows the East Africa Growth Accelerator and involves partnerships with GALVmed and the Bill & Melinda Gates Foundation. Elanco's commitment aligns with its 2030 sustainability goals, enhancing food security for local communities.
Elanco Animal Health reported a full-year 2021 revenue of $4,765 million, marking a 46% increase, largely due to Bayer Animal Health product integration. Despite a 2% decline in Q4 revenue to $1,113 million, adjusted EPS rose 75% to $0.21. Guidance for 2022 anticipates revenue between $4,745 million and $4,800 million, with adjusted EPS projected at $1.18 to $1.24. Significant innovation is expected, with $120 to $160 million in innovation revenue and 7 anticipated product approvals. Cost-cutting measures, including a reduction of 380 positions, aim to improve efficiency.
Elanco Animal Health (NYSE: ELAN) has appointed Rajeev (Bobby) Modi as executive vice president of U.S. Pet Health and Global Digital Transformation, effective March 14. Modi has two decades of experience in marketing and sales, previously serving at Conagra Brands and J.M. Smucker, where he led pet portfolio transformation. His role will focus on overseeing veterinary sales, retail, e-commerce, and preparing for upcoming product launches in the pet health pipeline. CEO Jeff Simmons highlighted Modi's expertise and vision for growing Elanco's pet health business.
Elanco Animal Health (NYSE: ELAN) is set to participate in the Cowen 42nd Annual Health Care Conference on March 7, 2022. CEO Jeff Simmons will engage in a virtual fireside chat at 2:50 p.m. ET. Attendees can access a live audio webcast via the "Events and Presentations" section on Elanco's investor website. A replay will be available for 30 days.
TriRx Pharmaceutical Services has completed the acquisition of Elanco Animal Health's manufacturing facility in Speke, UK, finalizing a two-facility sale that includes a site in Shawnee, Kansas. This strategic acquisition enhances TriRx's manufacturing capabilities for both animal and human health products, adding approximately 350 employees and advanced API and biological capacities. TriRx will support Elanco's long-term supply agreement, ensuring reliable product delivery. The acquisition marks a significant step in TriRx's growth strategy as it expands its global presence in the contract development and manufacturing sector.
Elanco Animal Health (NYSE: ELAN) will participate in the BofA Securities 2022 Virtual Animal Health Summit on February 24, 2022. Jeff Simmons, president and CEO, is scheduled for a virtual fireside chat at 1:35 p.m. ET. A live audio webcast will be accessible in the "Events and Presentations" section of Elanco’s investor website, with a replay available for 30 days.
Elanco Animal Health (NYSE: ELAN) will release its Q4 and full year 2021 financial results on February 24, 2022. A conference call detailing the company’s performance is scheduled for 8:00 a.m. ET that day, accessible via a live webcast on Elanco’s website. The company has a long-standing commitment to enhancing animal health and sustainability through innovative products and services, leveraging nearly 70 years of expertise in the industry.
The FDA has approved Zorbium, a new transdermal solution for managing postoperative pain in cats, marking a significant expansion of Elanco's pain management portfolio. This long-acting medication offers up to four days of postoperative pain control from a single dose, reducing the burden on pet owners for at-home medication administration. Anticipated to launch mid-year 2022, Zorbium underscores Elanco's commitment to innovation in veterinary pain relief, addressing an unmet market need.
Elanco Animal Health (NYSE: ELAN) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022. CEO Jeff Simmons is set to present at 10:30 a.m. ET, addressing questions from analysts. A live audio webcast of the event will be accessible on Elanco's investor website, with a replay available for 30 days afterward. Elanco is dedicated to improving animal health with nearly 70 years of experience, focusing on creating value for farmers and pet owners through innovative products and services.
FAQ
What is the current stock price of Elanco Animal Health (ELAN)?
What is the market cap of Elanco Animal Health (ELAN)?
